Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting
| Autor: | Suresh P. Jain, Jay S. Yadav, Gary S. Roubin, Larry S. Dean, Atul Mathur, Christopher M. Goods, Ming W. Liu, Khaled F. Al-Shaibi, Sriram S. Iyer, J.Michael Parks |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
medicine.medical_specialty Ticlopidine medicine.medical_treatment Coronary Disease Postoperative Complications Internal medicine medicine Humans Prospective Studies cardiovascular diseases Myocardial infarction Aged Chemotherapy Aspirin business.industry Stent Thrombosis Middle Aged equipment and supplies medicine.disease Treatment Outcome medicine.anatomical_structure Anesthesia Cardiology Drug Therapy Combination Female Stents Cardiology and Cardiovascular Medicine Complication business Platelet Aggregation Inhibitors Artery medicine.drug |
| Zdroj: | The American Journal of Cardiology. 78:1042-1044 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(96)00532-2 |
| Popis: | This prospective nonrandomized study was performed comparing aspirin alone (n = 46) versus aspirin and ticlopidine (p = 338) following native coronary artery stenting. There were significantly more stent thrombosis events in the aspirin-only group than in the aspirin and ticlopidine group (6.5% vs 0.9%, p = 0.02) and significantly more Q-wave myocardial infarctions and cardiac-related deaths in the aspirin-only group than in the aspirin and ticlopidine group (6.5% vs 0%, p = 0.002 and 4.4% vs 0.3% p = 0.02, respectively). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect